Intellia's Lonvo-z BLA Gets FDA Priority Review For Hereditary Angioedema; PDUFA Set For March 2027

Intellia Therapeutics said the FDA accepted its Biologics License Application for lonvoguran ziclumeran (lonvo-z) to treat hereditary angioedema and granted the therapy Priority Review. The expedited review is a meaningful regulatory milestone that could accelerate a potential commercial launch and is likely positive for NTLA shares.